TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.

Laurie H Sehn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.